A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. - Wikidata - wikimedia - TriplyDB

A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.

A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.

http://www.wikidata.org/entity/Q34619839

about

Combination pharmacotherapy for the treatment of neuropathic pain in adults Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature Vincristine-induced peripheral neuropathy in pediatric cancer patients A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Noradrenergic reuptake inhibition in the treatment of pain.Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial Topical analgesics for neuropathic pain: preclinical exploration, clinical validation, future development.Therapeutic strategies for cancer treatment related peripheral neuropathies.Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.Breast cancer survivorship issues.Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy Platinum-induced neurotoxicity and preventive strategies: past, present, and future The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study Novel Treatment of Radicular Pain With a Multi-Mechanistic Combination Topical Agent: A Case Series and Literature Review Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons.Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).Bottlenecks in the development of topical analgesics: molecule, formulation, dose-finding, and phase III design.High doses of topical amitriptyline in neuropathic pain: two cases and literature review.Chemotherapy-induced peripheral neuropathy: prevention and treatment.Neuropathic pain and pharmacological treatment.Methodological considerations in the design and implementation of clinical trials.Cancer treatment-related neuropathic pain syndromes--epidemiology and treatment: an update.Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.Drug combinations in the treatment of neuropathic pain.Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.Topical analgesics for neuropathic pain in the elderly: current and future prospects.Treatment of painful diabetic peripheral neuropathy.Skin Matters: A Review of Topical Treatments for Chronic Pain. Part Two: Treatments and Applications.Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives.Systematic review of topical amitriptyline for the treatment of neuropathic pain.Chemotherapy-induced peripheral neuropathy: a literature review.Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.

P2860

Q24202050-961F4555-10AB-4D38-9E87-1F1D02AD87A9 Q27007770-7D78A970-0E70-4B89-B7FC-2E45A2A262BC Q28078232-0CEF33B3-3846-4A60-9F4E-8392CBAB05A9 Q33693343-8FF5A909-94C4-4BB6-B3B5-89F05887EBBF Q33744706-A45F53ED-B307-49CD-95D1-50A1350F49D1 Q34304397-7ECCD3C6-B803-4AEA-9C4C-E394B23B721B Q34336573-9A7442E7-743B-48C4-BF5D-742A58EFD5F3 Q34376548-0BB0A8DC-075E-4FC2-AE31-95A8646BBD84 Q34433406-471EA8E7-BAA4-430E-86C6-0DAF96D1C2A9 Q34458581-05C90FAB-BC31-4B76-B5C7-3244495DCC72 Q34895561-EC030D40-D2EA-48E5-A86B-1831CABA20F7 Q35248222-6622A061-B9E8-49CC-8ABB-00235C8FDE4C Q35248891-8F656E8A-0FD2-44E0-8260-FEE53F356E4F Q35345734-C55712F7-6F65-45B9-9EF0-AA51E5F95CF6 Q35898601-DE5A61E7-32AB-48E0-AEF8-48D890F8E5AD Q36226275-C38C444A-E049-46A6-9DEB-D1A6E12F03AB Q36551631-5CD36701-28A4-411D-B0C2-837E70BF7EE6 Q36893328-10DEAD6B-EFC9-4BDC-A162-A4DA4A42F2C3 Q36950068-7A193C89-6459-45C8-98E2-B6AEACC29859 Q36977059-CDDE2123-5160-477F-AC1A-A30C991F2CDA Q37046151-FF011FAB-553C-4362-9804-14392FCE1D59 Q37170634-36714C6E-770D-4A41-8D5B-73034A4B0383 Q37364316-7F4722DE-6FA2-47BE-A409-33DB1E830CB6 Q37662241-6E22B366-37B8-49E4-8974-9D8950A3C46A Q37720689-3CB1B520-CC8C-4A2F-8B71-840355FBC5AB Q37890042-509F9E36-8748-47AD-AD66-C0F4349DFFCF Q37911252-37977AE3-ECB6-46E4-9C36-D6DA2F49FBD4 Q38113229-A8106979-B930-4816-98FA-1490D49A2AF4 Q38190172-A1C0C054-BC8F-452A-8A0F-3CA533CD7C90 Q38252761-5BB7BFC0-8C3E-4DB6-9937-0B7B3E5172E0 Q38254351-34267CE5-CD03-4CCA-9754-B91C39FCB2DA Q38258294-5560237B-ACD7-42F8-A102-D9C9901F036F Q38264622-765EF8B7-D3B5-4ADB-B198-8209FE27A903 Q38265422-BD541261-34A6-40BE-AC69-EBD90BA38FBF Q38329620-DA7730BA-315C-40C8-A92E-AB3E4AD9D8EA Q38335767-A40ACC3E-3983-4DB6-801A-3EE15B3297B6 Q38522262-242C4736-E952-4FC7-8C44-A6DBDA403C6F Q38523015-04FD46F1-AB3D-4ABA-912A-03575C159B5F Q38694811-61C09069-AAF0-4ECB-B2A2-B8F059CAA0C0 Q38716340-FFDE495D-0446-41F7-AAF1-E0B98902679A

P2860

A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.

http://www.wikidata.org/entity/Q34619839

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@ast

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@en

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@nl

type

label

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@ast

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@en

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@nl

prefLabel

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@ast

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@en

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@nl

P1433

Q34619839-45E7F823-0B02-455E-B9E6-9325575B41C6

P1476

Q34619839-E97AC33E-29E1-4D63-ADC1-B688490FD7D9

P2093

Q34619839-03891D21-0C61-4748-ABEE-A843336A6848

Q34619839-0AE780E5-96B9-4D18-BCB4-2E75C6AC2060

Q34619839-1CFD62CE-B145-426E-A0AB-8B6DDD57FD5A

Q34619839-3D088D72-247A-4188-9693-BD16FA3881FF

Q34619839-56072F1D-E56B-48BA-BCDE-3D3AA16AA4E1

Q34619839-691F8FE5-57DC-493E-B817-3CC700F63F75

Q34619839-6BEBD95D-3809-4CFE-95F5-0C02F875D0B1

Q34619839-809C38FF-25C0-4CF3-B1EB-1218360AB40E

Q34619839-84B72B0E-7B13-42BB-9759-EC1EE45CE6AE

Q34619839-895C95F3-2FE2-4C32-A9EB-4090BA17F9B7

P2860

Q34619839-0010A6E1-D1E7-4F0B-A8EA-8C68185CA621

Q34619839-0DBE14F0-5FA4-4EC7-A3D0-FAC2279E88D5

Q34619839-0DE89C14-D868-4E14-A643-DE7152733AD4

Q34619839-180584E5-D896-40FE-90C6-54EEC7367712

Q34619839-275ACBC3-15B2-4164-8970-C88920862A87

Q34619839-2E9927FD-1EE4-4028-A73B-DB1F6FA74625

Q34619839-3145B2BC-697A-4D37-96E6-4D0F484867B7

Q34619839-340E6585-B218-4C00-9094-887C603B48C0

Q34619839-35572772-935A-4408-ABC6-50B02F268DED

Q34619839-3696687A-E053-4A1D-A911-BDB16732D137

P2888

Q34619839-77B56CFD-446A-4ACA-B43E-D60F649355F7

P304

Q34619839-A74CFBD9-DF6D-43F2-A455-807112FE468A

P31

Q34619839-53D02057-4796-44AF-A90F-D9BC4D36E798

P356

Q34619839-CCADFB28-049D-4B66-B9BF-DBBF72A682F3

P433

Q34619839-87BB9FD3-610C-4CB3-B8AA-473A9DA44055

P478

Q34619839-21A0B8C7-81C9-46EA-AB1D-7D1AF3451486

P577

Q34619839-B526B9D0-E723-4316-BB00-EE787DF613F3

P5875

Q34619839-ACFCAF81-5005-4A65-90A0-93532B97C178

P698

Q34619839-5622C763-B27D-4AFE-B689-4D04DCA87795

P921

Q34619839-30C99DC8-5ABB-4F8E-8149-6A9A6B074039

Q34619839-EC0D84D3-06E0-4468-AA74-35EDAEB27C9D

P932

Q34619839-8CAB438D-0EA7-4C2A-A005-C38104BB6EF4

P356

S00520-010-0911-0

P1433

Supportive Care in Cancer

P1476

A double-blind, placebo-contro ...... neuropathy: NCCTG trial N06CA.

@en

P2093

Bassam I Mattar

http://www.w3.org/2001/XMLSchema#string

Bradley Christensen

http://www.w3.org/2001/XMLSchema#string

Charles L Loprinzi

http://www.w3.org/2001/XMLSchema#string

Debra L Barton

http://www.w3.org/2001/XMLSchema#string

Edward J Wos

http://www.w3.org/2001/XMLSchema#string

James Dewitt Bearden

http://www.w3.org/2001/XMLSchema#string

John W Kugler

http://www.w3.org/2001/XMLSchema#string

Kay L Hoff

http://www.w3.org/2001/XMLSchema#string

Keith S Lanier

http://www.w3.org/2001/XMLSchema#string

Kendrith M Rowland

http://www.w3.org/2001/XMLSchema#string

P2860

Pain assessment: global use of the Brief Pain Inventory

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Mechanisms of Disease: neuropathic pain—a clinical perspective

Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.

Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study.

Chemotherapeutic neuropathy.

Management of painful diabetic neuropathy.

Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy.

Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).

Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

P2888

s00520-010-0911-0

P304

833-841

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-010-0911-0

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44624285

http://www.w3.org/2001/XMLSchema#string

P698

20496177

http://www.w3.org/2001/XMLSchema#string

P921

P932

3338170

http://www.w3.org/2001/XMLSchema#string